Year None2022202120202019201820172016201520142013 Feb 28 View HTML version View PDF Version Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein Feb 26 View HTML version View PDF Version Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis Feb 26 View HTML version View PDF Version Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria Feb 18 View HTML version View PDF Version Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program Feb 17 View HTML version View PDF Version Regeneron Announces Investor Conference Presentations Feb 11 View HTML version View PDF Version Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting Feb 10 View HTML version View PDF Version FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Feb 4 View HTML version View PDF Version Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Feb 1 View HTML version View PDF Version Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting Jan 31 View HTML version View PDF Version CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »